TRIM16 transcription factor in prostate cancer

The aim of this investigation was to reveal the expression TRIM16, ERα, ERβ and AR in prostate cancer tissues compared to benign hyperplasia and clinical and morphological parameters.

Materials and methods. Fifty patients with locally advanced prostate cancer with T2-3N0M0 and twenty patients with benign hyperplasia were included in the study. Prostate cancer patients were divided into subgroups according the Gleason score. Nine patients had Gleason score of 6, eighteen patients had 7 Gleason score, seven patients got 8 Gleason score and seven patients got 9 Gleason score. PSA level was from 4 to 100 ng/ml. TRIM16, ERα, ERβ and AR expression was determined by PCR in real time.

Results. Increase of TRIM16 expression in prostate cancers was accompanied by high AR and ERα expression. The onco-suppressor ERβ was not changed in cancer tissues compared to benign hyperplasia. The Gleason score level was dependent on AR/ERβ relation. Associations between the PSA, AR, ERβ and TRIM16 were found in prostate cancers

Conclusion. Transcription factor TRIM16 participated in prostate cancer development. The connection between the ER and AR expression and clinical and morphological factors was found.

prostate cancer, transcription factor TRIM16, AR, ERα, ERβ

1. Amiya Y., Yamada Y., Sugiura M., Sasaki M., Shima T., Suzuki N., Nakatsu H., Murakami S., Shimazaki J. Treatment of locally advanced prostate cancer (Stage T3). Jpn. J. Clin. Oncol. 2017; 47 (3): 257–261. DOI: 10.1093/jjco/hyw186.

2. Markova A.S., Polikarpova S.B., Kamolov B.S., Gridneva Y.V., Kalinin S.A., Peters M.V., Matveev V.B. Predictors of overall survival in patients with metastatic castration-resistant prostate cancer. Cancer Urology. 2015; 11 (2): 77–84 (in Russ.). DOI: 10.17650/1726-97762015-11-2-77-84.

3. D’Amico A.V., Moul J., Carroll P.R., Sun L., Lubeck D., Chen M.H. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J. Urol. 2004; 172 (5 Pt 2): 42–46.

4. Ozato K., Shin D.M., Chang T.H., Morse H.C. 3rd. TRIM family proteins and their emerging roles in innate immunity. Nat. Rev. Immunol. 2008; 8 (11): 849–860. DOI: 10.1038/nri2413.

5. Kim P.Y., Rahmanto A.S., Tan O., Norris M.D., Haber M., Marshall G.M., Cheung B.B. TRIM16 overexpression induces apoptosis through activation of caspase-2 in cancer cells. Apoptosis. 2013; 18 (5): 639–651. DOI: 10.1007/s10495-013-0813-y.

6. Kim P.Y., Tan O., Liu B., Trahair T., Liu T., Haber M., Norris M.D., Marshall G.M., Cheung B.B. High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients. Cancer Lett. 2016; 374 (2): 315–323. DOI: 10.1016/j.canlet.2016.02.021.

7. Kimsa M.W., Strzalka-Mrozik B., Kimsa M.C., Mazurek U., Kruszniewska-Rajs C., Gola J., Adamska J., Twardoch M. Differential expression of tripartite motif-containing family in normal human dermal fibroblasts in response to porcine endogenous retrovirus infection. Folia Biol (Praha). 2014; 60 (3): 144–151.

8. Bell J.L., Malyukova A., Holien J.K., Koach J., Parker M.W., Kavallaris M., Marshall G.M., Cheung B.B. TRIM16 acts as an E3 ubiquitin ligase and can heterodimerize with other TRIM family members. PLoS One. 2012; 7 (5): 37470. DOI: 10.1371/journal.pone.0037470. Epub 2012 May 21.

9. Raif A., Marshall G.M., Bell J.L., Koach J., Tan O., D’andreti C., Thomas W., Sekyere E., Norris M., Haber M., Kavallaris M., Cheung B.B. The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylation. Cancer Lett. 2009; 277 (1): 82–90. DOI: 10.1016/j.canlet.2008.11.030.

10. Qi L., Lu Z., Sun Y.H., Song H.T., Xu W.K. TRIM16 suppresses the progression of prostate tumors by inhibiting the Snail signaling pathway. Int J. Mol. Med. 2016; 38 (6): 1734–1742. DOI: 10.3892/ijmm.2016.2774.

11. Cheung B.B., Koach J., Tan O., Kim P., Bell J.L., D’andreti C., Sutton S., Malyukova A., Sekyere E., Norris M., Haber M., Kavallaris M., Cunningham A.M., Proby C., Leigh I., Wilmott J.S., Cooper C.L., Halliday G.M., Scolyer R.A., Marshall G.M. The retinoid signalling molecule, TRIM16, is repressed during squamous cell carcinoma skin carcinogenesis in vivo and reduces skin cancer cell migration in vitro. J. Pathol. 2012; Feb; 226 (3): 451–462. DOI: 10.1002/path.2986.

12. Sutton S.K., Koach J., Tan O., Liu B., Carter D.R., Wilmott J.S., Yosufi B., Haydu L.E., Mann G.J., Thompson J.F., Long G.V., Liu T., McArthur G., Zhang X.D., Scolyer R.A., Cheung B.B., Marshall G.M. TRIM16 inhibits proliferation and migration through regulation of interferon beta 1 in melanomacells. Oncotarget. 2014; 5 (20): 10127–10139.

13. Tan H., Liu Z., Qi J., Chu G. Tripartite motif 16 inhibits the migration and invasion in ovarian cancer cells. Oncol. Res. 2017; 25 (4): 551–558. DOI: 10.3727/096504016X14758370595285.

14. Gorbunov A.K., Spirina L.V., Usynin E.A., Slonimskaya E.M. Role of transcription factor Brn-3α in prostate cancer, connection with hormone reception and AKT/m-TOR signaling pathway activation. Uspekhi molekulyarnoy onkologii – Success of Molecular Oncology. 2016; 3 (3): 54 (in Russ.).

15. Spirina L.V., Gorbunov A.K., Chigevskaya S.Y., Kondakova I.V., Slonimskaya E.M., Usynin E.A., Choinzonov E.L., Zaitseva O.S. Transcription factor Brn-3a mRNA in cancers, relationship with AR, ER receptors and AKT/m-TOR pathway components. AIP Conference Proceedings. 2017; 1882, 02007. DOI: 10.1063/1.5001650.

16. Vamesu S. Angiogenesis and ER/PR status in primary breast cancer patients: an analysis of 158 needle core biopsies. Rom. J. Morphol. Embryol. 2007; 48: 25–31.

17. Ahmad N., Kumar R. Steroid hormone receptors in cancer development: A target for cancer therapeutics. Cancer Letters. 2011; 300: 1–9. DOI: 10.1016/j.canlet.2010.09.008.

18. Nelson A.W., Tilley W.D, Neal D.E., Carroll J.S. Estrogen receptor beta in prostate cancer: friend or foe? Endocr. Relat. Cancer. 2014; 21 (4): T219–234. DOI: 10.1530/ERC-13-0508.

19. Izumi K., Mizokami A., Lin W.J., Lai K.P., Chang C. Androgen receptor roles in the development of benign prostate hyperplasia. Am. J. Pathol. 2013; 182 (6): 1942–1949. DOI: 10.1016/j.ajpath.2013.02.028. Epub 2013 Apr 6.

20. Dunsmuir W.D., Gillett C.E., Meyer L.C., Young M.P., Corbishley C., Eeles R.A., Kirby R.S. Molecular markers for predicting prostate cancer stage and survival. BJU Int. 2000; 86 (7): 869–878.

21. Yeh C.-R., Da J., Song W., Fazili A., Yeh S. Estrogen receptors in prostate development and cancer. American Journal of Clinical and Experimental Urology. 2014; 2 (2): 161–168.

22. Latil A., Bièche I., Vidaud D., Lidereau R., Berthon P., Cussenot O., Vidaud M. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res. 2001; 61 (5): 1919–1926.

23. Bedarshi B., Mohamad I.B., Harsh K., Tushar K., Rupali B. Correlation between prostate specific antigen levels and various prostatic pathologies. Journal of Medical Society. 2016; 30: 172–175. DOI: 10.4103/0972-4958.191184.

24. Mizokami A., Izumi K., Konaka H., Kitagawa Y., Kadono Y., Narimoto K., Nohara T., Bahl A.K., Namiki M. Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice. Asian. J. Androl. 2017; 19 (2): 143–148. DOI: 10.4103/1008-682X.179159.